Loading...
Symbols:
Loading...
Symbols:
Bristol-Myers Squibb Co. (BMY)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Bristol-Myers Squibb Co. (BMY)
170 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on BMY
- SA Editor Miriam Metzinger(30)
- Mike Huckman(25)
- SA Editor Eli Hoffmann(12)
- Mike Havrilla(12)
- SA Editor Joan Wickham(9)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(576)
- Bill Cara(432)
- David Merkel(403)
- SA Editor Eli Hoffmann(387)
- Mike Stathis (338)
Most commented on authors
- SA Editor Eli Hoffmann(77)
- Mike Stathis (61)
- SA Editor Rachael Granby(54)
- SA Editor Joan Wickham(32)
- Zacks.com (27)
- Thanksgiving Economic Data: Mostly Turkeys
- Stocks Offering 'Healthy' Returns
- Bristol-Myers' Collaboration with Exelixis Is Looking Lucrative
- China Biopharma News Back in the Spotlight
- Navigating the Micro-Cap Biotech Minefield
- Markets Strike Fresh Lows
- Big Pharma Steps Up China Investment
- How Pharma Is Faring in the Financial Crisis
- Parsing the Dismal October Employment Report
- Reality Check on the Big Pharma Rumor Mill
- Wall Street Breakfast: Must-Know News
- Earnings Preview: Bristol Myers Squibb
- Ten Highest Yielding Pharma Stocks
- Even Fatter Yields for Pfizer; M&A Targets in the Sector
- 11 More Potential Buys
- Is It Safe?
- Potential Short Trades on Pending FDA Decisions
- Some Good News in Biotech
- Four Thoughts on the Imclone/Lilly Deal
- Discovery Labs: The Next Biotech Buy?
- Wall Street Breakfast: Must-Know News
- Eli Lilly Sinks In After-Hours Trading On Effient Delay
- Pharmaceuticals: Near Term Movers Based On FDA Decision Dates
- Would a Lilly/Imclone Deal Make Sense?
- Licensing Deal Is Imminent for ArQule
- Wall Street Breakfast: Must-Know News
- Wall Street Breakfast: Must-Know News
- Predictions on Imclone's Suitors
- Lilly Sinks After Hours on Effient Delay
- FDA Decision Calendar: Some Potentially Prominent Decisions in Early 2009
- Wall Street Breakfast: Must-Know News
- Roche Covets Genentech for Good Reason
- Has Urgency Left - Fast Money Recap (9/23/08
- Wall Street Breakfast: Must-Know News
- BMY Ups the Ante on ImClone
- Bristol-Myers Raises ImClone Offer to $62
- Eli Lilly Moves on News of Its New Bloodthinner
- Nine Stocks Going Ex-Dividend in October
- Bristol-Meyers Squibb vs. Imclone: Icahn Stirs Up the Pot
- Status Report: ImClone Systems - Bristol-Myers Squibb
- Ownership of Erbitux Follow-On Is Central to ImClone Takeover
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »